4//SEC Filing
Forman Mark S 4
Accession 0001209191-24-000369
CIK 0001787297other
Filed
Jan 2, 7:00 PM ET
Accepted
Jan 3, 4:21 PM ET
Size
9.7 KB
Accession
0001209191-24-000369
Insider Transaction Report
Form 4
Forman Mark S
Chief Medical Officer
Transactions
- Sale
Common Stock
2024-01-02$0.91/sh−15,813$14,390→ 45,269 total - Exercise/Conversion
Common Stock
2023-12-31+50,000→ 61,082 total - Exercise/Conversion
Restricted Stock Unit
2023-12-31−50,000→ 0 total→ Common Stock (50,000 underlying)
Footnotes (5)
- [F1]Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
- [F2]Includes 3,082 shares acquired on May 13, 2022, 4,000 shares acquired on May 15, 2023, and 4,000 shares acquired on November 15, 2023 under the 2020 Employee Stock Purchase Plan.
- [F3]The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
- [F4]Each RSU represents a contingent right to receive one share of Issuer's common stock.
- [F5]100% of the total restricted stock units vested on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Documents
Issuer
Passage BIO, Inc.
CIK 0001787297
Entity typeother
Related Parties
1- filerCIK 0001922353
Filing Metadata
- Form type
- 4
- Filed
- Jan 2, 7:00 PM ET
- Accepted
- Jan 3, 4:21 PM ET
- Size
- 9.7 KB